Dr Mark Kris discusses the increasing precision of lung cancer therapies and the need for additional testing to find ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced the launch of a new program specifically geared towards using ...
Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif.--(BUSINESS WIRE)-- ...
BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...
Boston Cell Standards today announced the publication of the CASI-01 study in Lancet: eBioMedicinedemonstrating that calibration dramatically improves the accuracy and reproducibility of ...
Collaboration to produce a machine learning (ML)-based tool that automatically analyzes images of HER2 immunohistochemistry (IHC)-stained tissue slides and reports metrics that can be used to monitor ...
On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests. This addition will help oncologists identify the ...
The Texas A&M Veterinary Medical Diagnostic Laboratory has resumed immunohistochemistry (IHC) testing for chronic wasting disease after a national supply shortage of reagents grinded the process to a ...
New RNA-based algorithm is now available with the xR assay “This program is truly the intersection of all three of our business units – genomics, AI applications, and data – leveraging our deep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results